The FDA’s Big Fat Hydroxychloroquine Blunder

The blunder is in this comment from the FDA’s revocation of its EUA for hydroxychloroquine: Hospitalized patients were likely to have greater prospect of benefit (compared to ambulatory patients with mild illness) and could be more closely monitored for potential toxicity, although it was recognized that enrollment in a clinical trial would be the best